Dernières nouvelles pour H-Source Holdings (OTC:HSCHF) Stock

H-Source Holdings Ltd is a technology company which has an experience in hospital and supply chain systems. The firm has developed a digital platform and network to operate in the healthcare industry and offers a private, hospital-to-hospital marketplace that allows members to buy, sell, and transfer inventory supplies and capital equipment with each other. Members can conduct secure transactions within Integrated Delivery Networks (IDNs), Group Purchasing Organizations (GPOs) or customize their own group of hospitals using the company's built-in filters to reduce health care costs and medical products waste.

H-SOURCE HLDG LTD A by H-Source Holdings Ltd.

H-Source Holdings Ltd

Morgan Stanley analyst Richard Hill maintains Safehold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAFE#NYSE">SAFE</a>) with a Equal-Weight and lowers the price target from $19 to $17.

News

Price Target

Analyst Ratings

SAFE

Morgan Stanley Maintains Equal-Weight on Safehold, Lowers Price Target to $17

Cantor Fitzgerald analyst Steven Seedhouse initiates coverage on InflaRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFRX#NASDAQ">IFRX</a>) with a Overweight rating and announces Price Target of $10.

Initiation

IFRX

Cantor Fitzgerald Initiates Coverage On InflaRx with Overweight Rating, Announces Price Target of $10

DA Davidson analyst Russell Gunther maintains Meridian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRBK#NASDAQ">MRBK</a>) with a Buy and lowers the price target from $19 to $18.

MRBK

DA Davidson Maintains Buy on Meridian, Lowers Price Target to $18

Editor&#8217;s Note: The story has been updated to mention acquisition of &#8216;net assets&#8216;
Nuvve Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>) on Tuesday announced the acquisition of substantially all of the net assets of Fermata Energy LLC, a V2G platform provider in the U.S.
The acquisition was completed through Nuvve&#8217;s newly formed subsidiary, Fermata II LLC (Fermata 2.0), which focused on scaling intelligent, bidirectional energy solutions.
Fermata 2.0 acquired substantially all of the assets of Fermata and assumed certain specified liabilities. It issued 4,900,000 shares of convertible preferred stock to former Fermata debt holders as part of the transaction. The total purchase price is approximately $659,000, consisting of $340,000 in cash and the remainder in assumed liabilities.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/04/44959619/exclusive-defi-development-adds-9-9-million-in-solana-tokens-underscoring-its-commitment-towards-digital-asset-treasury-strategy" rel="noreferrer noopener">EXCLUSIVE: DeFi Development Adds $9.9 Million In Solana Tokens Underscoring Its Commitment Towards Digital Asset Treasury Strategy</a>
Nuvve intends to raise additional capital to support future operational funding needs by offering up to 25% equity in Fermata 2.0.
On Monday, Nuvve launched a new wholly owned subsidiary&nbsp;that is investing in digital assets <a target="_blank" href="https://www.benzinga.com/news/25/04/45046313/nuvve-expands-beyond-evs-with-bold-bitcoin-crypto-investment-arm" rel="noreferrer noopener">and blockchain ventures</a>.
The move signals a broader shift for the company as it seeks to tap into emerging technologies beyond its focus on grid modernization and vehicle-to-grid (V2G) services.
Fermata 2.0 will be jointly led by Gregory Poilasne as CEO and Hamza Lemsaddek as Chief Operating Officer.
Immediate operational efficiencies include consolidating software platform teams and AWS infrastructure within Fermata 2.0, significantly reducing annual expenses by approximately $2 million. Sales synergies are emerging as Nuvve expands its hardware offerings into markets previously served by Fermata.
Joint engineering and R&amp;D initiatives will pursue innovation and collaborative grant-funded projects, further supported by the combined Nuvve and Fermata IP and engineering resources.
Fermata 2.0 will deliver a new generation of white-label software solutions, combining Fermata&#8217;s optimization and forecasting capabilities with Nuvve&#8217;s advanced AI-driven grid intelligence.
The assets acquisition strengthens Nuvve&#8217;s comprehensive intellectual property portfolio, diversifies market risk, and enhances its range of U.S.-built certified hardware through Fermata&#8217;s established domestic manufacturer relationships, adding resilience amid evolving tariff policies.
This assets acquisition also positions Nuvve to capitalize on accelerating regulatory tailwinds such as the Inflation Reduction Act and state-level grid modernization incentives, further expanding the total addressable market for V2G applications.
Fermata 2.0 is positioned to play a critical role in Nuvve&#8217;s growth strategy as the company expands its presence in behind-the-meter markets and strengthens its VPP services across regulated and deregulated markets alike, with the potential to drive incremental revenue from new white-label licensing opportunities, expanded DER optimization contracts, and fleet electrification partnerships.
It also provides a focused investment vehicle within Nuvve for scaling software-first energy services.
In February, Nuvve was awarded a $400 million contract from the State&nbsp;<a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/02/44051830/whats-going-on-with-nuvve-shares-friday" rel="noreferrer noopener">of New Mexico</a>.
Under the contract, Nuvve will provide a comprehensive, turnkey electrification solution over the next four years to support New Mexico&#8217;s adoption of zero-emission vehicles and renewable energy goals.
Price Action: At the last check on Tuesday, NVVE stock was trading 3% higher to $0.89 during the premarket session.

Exclusives

General

NVVE

CORRECTION: EXCLUSIVE: Nuvve Acquires Fermata Energy Assets, Says Deal Adds Resilience Amid Evolving Tariff Policies

Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) is set to release its <a href="https://www.benzinga.com/earnings?tickers=META" target="_blank" rel="noopener">first-quarter earnings</a> report, with Wall Street on edge and charts sending mixed signals.
Meta stock has soared 27% over the past year but has been stumbling in 2025, down more than 8% year to date and over 4% in the past month.
Now, with earnings due Wednesday after the bell, investors are deciding whether Meta's momentum can return &#8211; or whether it&#8217;s stuck in a sideways scroll.
<h2 class="wp-block-heading">Earnings Incoming: Will Ad Strength Power Meta's Next Move?</h2>
Expectations are lofty. According to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0429" target="_blank" rel="noopener">Benzinga Pro</a> data, Wall Street analysts expect Meta to post earnings per share of $5.28 on $41.39 billion in revenue. Hightower's chief investment strategist, Stephanie Link, is optimistic. She's betting Google's strong ad showing signals good news for Meta, which derives a staggering "96% of its revenues" from advertising.
Read Also: <a href="https://www.benzinga.com/general/education/25/04/45059231/mark-zuckerberg-says-theres-going-to-have-to-be-a-reckoning-about-college-degrees-and-whether-theyre-truly-worth-it-anymore">Mark Zuckerberg Says &#8216;Reckoning&#8217; For College Degrees Is Nearing As Student Debt Balloons: &#8216;You&#8217;re Starting Off In This Big Hole&#8217;</a>
<h2 class="wp-block-heading">Valuation Vs. Volatility: Stephanie Link Sees Growth At A Discount</h2>
Link is calling for "20% total return growth and 40% operating margins" powered by Meta's massive 3.3 billion-user base.
And valuation-wise? "Stock trades at 17x 2026 estimates, which seems cheap to me – as growth continues at a reasonable price," she told Benzinga via email.
<h2 class="wp-block-heading">Mixed Signals: META Stock Technical Indicators Tell A Split Story</h2>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0429"><img loading="lazy" decoding="async" width="627" height="489" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29064803/Screenshot-2025-04-29-at-3.33.59-PM.png" alt="" class="wp-image-892531" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29064803/Screenshot-2025-04-29-at-3.33.59-PM.png 627w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29064803/Screenshot-2025-04-29-at-3.33.59-PM-300x234.png 300w" sizes="(max-width: 627px) 100vw, 627px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0429">Chart created using Benzinga Pro</a>
Still, technical signals are throwing up a few caution flags. Meta stock, at $549.74 sits comfortably above its eight-day and 20-day simple moving averages &#8211; both bullish signals &#8211; but it's below its 50-day and 200-day averages, which paints a bearish picture in the longer term. The Moving Average Convergence Divergence (MACD) is a negative 18.13, and the Relative Strength Index (RSI) sits at a neutral 49.78 &#8211; suggesting the stock's energy is, for now, in limbo.
In short, Meta's story is stuck between a fundamental feel-good narrative and a technically uncertain tape. With earnings on deck and ad momentum behind it, Wednesday&#8217;s results could be the spark that decides whether Meta scrolls higher—or stays stuck in the feed.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45037345/microsoft-meta-amazon-apple-gear-up-for-ai-revolution-week-as-tariff-storm-brews">Microsoft, Meta, Amazon, Apple Gear Up For &#8216;AI Revolution&#8217; Week As Tariff Storm Brews</a></li>
</ul>
Photo: Shutterstock

Technicals

Previews

Tech

Trading Ideas

Meta Q1 Earnings On Deck: Expert Sees Growth At A 'Reasonable Price'

Cantor Fitzgerald analyst Steven Seedhouse initiates coverage on BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Overweight rating and announces Price Target of $20.

BCRX

Cantor Fitzgerald Initiates Coverage On BioCryst Pharma with Overweight Rating, Announces Price Target of $20

Morgan Stanley analyst James Faucette maintains Q2 Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QTWO#NYSE">QTWO</a>) with a Equal-Weight and lowers the price target from $95 to $89.

QTWO

Morgan Stanley Maintains Equal-Weight on Q2 Holdings, Lowers Price Target to $89

DA Davidson analyst Gary Tenner maintains Sierra (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSRR#NASDAQ">BSRR</a>) with a Buy and lowers the price target from $37 to $36.

BSRR

DA Davidson Maintains Buy on Sierra, Lowers Price Target to $36

Guidance

NEOV

NeoVolta Says Apr. Revenue Projected To Exceed $2M

HAFC

Hanmi President And CEO Bonnie Lee Releases Shareholder Letter Titled "Successfully Navigating a Dynamic Market Environment"

DA Davidson analyst Thomas Diffely maintains Amkor Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) with a Buy and lowers the price target from $36 to $30.

AMKR

DA Davidson Maintains Buy on Amkor Tech, Lowers Price Target to $30

American Tower Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>) reported first-quarter financial results before the market open on Tuesday. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/04/b45062389/american-tower-corporation-reports-first-quarter-2025-financial-results">of the report</a>.
Q1 Earnings: American Tower reported first-quarter revenue of $2.56 billion, beating analyst <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $2.54 billion, according to estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company also reported adjusted funds from operations (AFFO) of $2.75 per share, beating estimates of $2.58 per share.
Total revenue was up 2% year-over-year, while property revenue increased 0.2%. At quarter&#8217;s end, the company had approximately $11.7 billion of total liquidity, consisting of approximately $2.1 billion in cash and cash equivalents.
&#8220;Together with the resilient demand we&#8217;re seeing for our portfolio of assets, we remain focused on enhancing the quality of our earnings through active portfolio management, organizational and operational efficiency, disciplined capital allocation and a strong balance sheet, positioning us to better navigate ongoing macroeconomic uncertainty while continuing to meet our customers&#8217; critical connectivity needs,&#8221; said Steven Vondran,&nbsp;CEO of American Tower. 
See Also: <a href="https://www.benzinga.com/25/04/45064454/this-trade-desk-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-tuesday">This Trade Desk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday</a>
Outlook: American Tower expects total property revenue in 2025 to be between $9.97 billion and $10.12 billion. The company also raised its full-year AFFO guidance from a range of $10.31 to $10.50 to a new range of $10.35 to $10.54 per share, versus estimates of $10.39 per share.
AMT Price Action: <a href="http://benzinga.com/quote/amt">American Tower shares</a> were up 0.57% at $212.50 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: katjen/Shutterstock.

Movers

American Tower Reports Q1 Earnings: The Details

Morgan Stanley analyst Erik Woodring maintains Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with a Overweight and raises the price target from $220 to $235.

AAPL

Morgan Stanley Maintains Overweight on Apple, Raises Price Target to $235

<ul>
<li>Following last week's <a href="https://www.whitehouse.gov/presidential-actions/2025/04/unleashing-americas-offshore-critical-minerals-and-resources/">Executive Order</a>, ‘Unleashing America's Offshore Critical Minerals and Resources', TMC USA has submitted applications to the National Oceanic and Atmospheric Administration (NOAA) for two exploration licenses and one commercial recovery permit under the Deep Seabed Hard Mineral Resources Act (DSHMRA)</li>
<li>The commercial recovery permit application advances TMC's timeline ahead of its original June 27 application target, further strengthening the Company's leadership in the deep-sea minerals sector</li>
<li>The application area for the commercial recovery permit, TMC USA-A_2, covers a total combined area of 25,160 square kilometers in the Clarion Clipperton Zone which includes areas that contain the Company's already indicated and measured resources</li>
<li>TMC USA has also submitted two exploration license applications: TMC USA-A and TMC USA-B with a total combined area of 199,895 square kilometers</li>
<li>We believe the TMC USA-A and USA-B exploration areas contain SEC SK 1300-compliant resources of 1,635 million wet tonnes of polymetallic nodules, with an additional estimated 500 million tonnes of exploration upside. Together, the resource is estimated to contain approximately 15.5 million tonnes of nickel, 12.8 million tonnes of copper, 2.0 million tonnes of cobalt, and 345 million tonnes of manganese &nbsp;</li>
</ul>
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- TMC the metals company Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMC#NASDAQ">TMC</a>) (TMC or the Company), an explorer of the world's largest undeveloped resource of critical metals for infrastructure, defense, energy and future technologies, today announced that its U.S. subsidiary, The Metals Company USA LLC (TMC USA), has submitted applications for a commercial recovery permit and two exploration licenses under the Deep Seabed Hard Mineral Resources Act (DSHMRA) and National Oceanic and Atmospheric Administration (NOAA) implementing regulations which form the U.S. seabed mining code.

TMC USA Submits Application For Commercial Recovery Of Deep-Sea Minerals In High Seas Under U.S. Seabed Mining Code

Morgan Stanley analyst Craig Hettenbach maintains Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) with a Equal-Weight and lowers the price target from $60 to $40.

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Morgan Stanley Maintains Equal-Weight on Hims & Hers Health, Lowers Price Target to $40

– New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus in people with primary biliary cholangitis (PBC) –
– Additional presentations will showcase the potential for maintained virologic response following treatment with investigational bulevirtide in people with hepatitis delta virus (HDV) –
– Presentations in hepatitis B virus (HBV) and hepatitis C virus (HCV) will underscore Gilead's commitment to advancing scientific research and our understanding of viral hepatitis in the real-world setting –

Biotech

Events

GILD

Gilead To Present New Research To EASL Congress

Franklin Financial Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRAF#NASDAQ">FRAF</a>) reported quarterly earnings of $0.88 per share. This is a 14.29 percent increase over earnings of $0.77 per share from the same period last year. The company reported $20.17 million in sales this quarter. This is a 13.68 percent increase over sales of $17.74 million the same period last year.

Earnings

FRAF

Franklin Financial Servs Q1 EPS $0.88 Up From $0.77 YoY, Sales $20.17M Up From $17.74M YoY

ASBP

Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval For In-Human Clinical Trial Protocol Of Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Outperform rating and announces Price Target of $5.

PRQR

Evercore ISI Group Initiates Coverage On ProQR Therapeutics with Outperform Rating, Announces Price Target of $5

Tempus AI Announces Publication Of Its Study 'Analytical Validation of NGS-based Comprehensive Liquid Biopsy Assay for Therapy' In The Journal of Molecular Diagnostics

Comments

H-Source Holdings

Actualités

Dernières nouvelles pour H-Source Holdings (OTC:HSCHF) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL